NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:US Cancer Vaccine Market Analysis
Cancer vaccines are highly researched today owing to growing cancer incidences and an urgent need to control and prevent the massively penetrating disease. Amongst the highest incident cancers, prostate cancers are high in males and breast cancer in females. The introduction of Merck's Gardasil bought great attention to cancer vaccines. US represents the most promising market for cancer vaccines across the globe, accounting for around 49% share.
The prophylactic vaccines currently available in the market include Merck's Gardasil, GSK's Cervarix, and several other Hepatitis B vaccines while the only therapeutic vaccine in the market is Dendreon's Provenge. The report "US Cancer Vaccine Market Analysis", in such a scenario provides an analysis of the current market size for these vaccines along with future estimations. In-depth perspective has been provided for the various factors that will govern the growth of each of these vaccines along with the constraints that limit them.
Merck and GSK are expected to continue to be undefeated market leaders in the prophylactic cancer segment as the launch of a new cancer vaccine is unlikely in the next 3 years. The research and innovation for cancer vaccines is highly robust and several candidates are being studied for their role in cancer. Trials are focusing more on the therapeutic vaccines and this segment can be expected to evolve greatly in the years to come. Amongst the various studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as Lucanix and Stimuvax having entered phase 3 trials.
The report also covers the FDA's vaccine approval process and its guidance to the industry for developing therapeutic cancer vaccines. The therapeutic vaccines currently account only for about 15% share in the US cancer vaccine market but this share can be expected to increase drastically post 2016 with such high focus on developing therapeutics for other cancer types.
The report "US Cancer Vaccine Market Analysis", is an outcome of an extensive research and prudent analysis of the cancer vaccine market in the world and in US. It provides an effective analysis of the market drivers, current market size, and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Further, the report provides an in-depth analysis on the pipeline cancer vaccines in phase 1-4 clinical stages for most prevalent cancers in US. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines for clinical proceedings of cancer therapeutic vaccines has also been provided. The report also provides competitive analysis of the promising players in the market along with their key strategies to increase their penetration in the market.
1. Analyst View2. Research Methodology3. Cancer Statistics by Demographics3.1 Prevalence, Incidences and Mortality (2008-2016)3.2 Leading States by Incidence3.3 Leading Cancers by Incidence3.3.1 Male Cancer Incidences3.3.2 Female Cancer Incidences3.3.3 Age-Group4. Cancer Vaccines Market Outlook4.1 Market Analysis and Segmentation4.2 Key Product Analysis4.2.1 Provenge220.127.116.11 Market Analysis18.104.22.168 Restraints4.2.2 HPV Vaccine22.214.171.124 Gardasil126.96.36.199.1 Market Analysis188.8.131.52.2 Restraints184.108.40.206 Cervarix220.127.116.11.1 Market Analysis18.104.22.168.2 Restraints4.2.3 HBV Vaccines22.214.171.124 Market Analysis126.96.36.199 Market Restraints188.8.131.52.1 Engerix-B and Twinrix184.108.40.206.2 Recombivax HB and Comvax220.127.116.11.3 Pediarix5. Potential Cancer Vaccine Candidates: An Opportunity Assessment5.1 Prophylactic Vaccine5.2 Therapeutic Vaccine5.2.1 Prostate Cancer5.2.2 Breast Cancer5.2.3 Lung Cancer5.2.4 Colorectal Cancer6. Regulatory Environment6.1 Vaccine Approval Process6.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines6.2.1 Considerations for both Early and Late Phase Clinical Trials18.104.22.168 Patient Population22.214.171.124 Monitoring the Immune Response126.96.36.199 Biomarkers as Evidence of Efficacy188.8.131.52 Adjuvants Used to Stimulate Immune Response184.108.40.206 Multi-antigen Vaccines220.127.116.11 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines18.104.22.168 Concomitant and Subsequent Therapies6.2.2 Considerations for Early Phase Clinical Trials22.214.171.124 Starting Dose and Dosing Schedule126.96.36.199 Booster and Maintenance Therapy188.8.131.52 Dose Escalation184.108.40.206 Single-arm versus Randomized Phase-2 Trials in Early Development6.2.3 Considerations for Late Phase Clinical Trials220.127.116.11 Safety Profile from Early Phase Clinical Trials18.104.22.168 Endpoints22.214.171.124 Statistical Issues126.96.36.199 Control Issues188.8.131.52 Delayed Vaccine Effect184.108.40.206 Autologous Vaccine Trials220.127.116.11 Accelerated Approval Regulations7. Competitive Landscape7.1 Merck & Co.7.1.1 Business Description7.1.2 Key Strategy Analysis7.2 GSK7.2.1 Business Description7.2.2 Key Strategy Analysis7.3 Dendreon7.3.1 Business Description7.3.2 Key Strategy Analysis7.4 Bavarian Nordic7.4.1 Business Description7.4.2 Key Strategy Analysis7.5 Celldex Therapeutics7.5.1 Business Description7.5.2 Key Strategy Analysis7.6 Kael-GemVax7.6.1 Business Description7.6.2 Key Strategy Analysis7.7 Oxford BioMedica7.7.1 Business Description7.7.2 Key Strategy Analysis7.8 Galena Biopharma7.8.1 Business Description7.8.2 Key Strategy Analysis
List of Figures:
Figure 3-1: Cancer Prevalence (Million), 2008-2016Figure 3-2: Cancer Incidences ('000), 2008-2016Figure 3-3: Cancer Mortality ('000), 2008-2016Figure 3-4: Incidences by Type of Cancer (%), 2012Figure 3-5: Top Five States with Highest Cancer Incidences ('000), 2012Figure 3-6: Cancer Incidences by Age Group (%)Figure 4-1: Global - Cancer Vaccine Market (Billion US$), 2010-2012Figure 4-2: Cancer Vaccine Market (Billion US$), 2010-2012Figure 4-3: Share of US in Global Cancer Vaccine Market (2012)Figure 4-4: Cancer Vaccine Market by Product Type (%), 2012Figure 4-5: Provenge Market (Million US$), 2010-2012Figure 4-6: Global - Gardasil Market (Million US$), 2010-2012Figure 4-7: Gardasil Market (Million US$), 2010-2012Figure 4-8: Share of US in Global Gardasil Sales (2012)Figure 4-9: Global - Cervarix Market (Million US$), 2010-2012Figure 4-10: Cervarix Market (Million US$), 2010-2012Figure 4-11: Share of US in Global Cervarix sales (2012)Figure 4-12: Global - Hepatitis B Vaccine Market (Billion US$), 2010-2012Figure 4-13: Hepatitis B Vaccine Market (Million US$), 2010-2012Figure 4-14: Global - Engerix-B and Twinrix Market (Million US$), 2010-2012Figure 4-15: Engerix-B and Twinrix Market (Million US$), 2010-2012Figure 4-16: Global - Recombivax Market (Million US$), 2010-2012Figure 4-17: Recombivax Market (Million US$), 2010-2012Figure 4-18: Global - Pediarix Market (Million US$), 2010-2012Figure 4-19: Pediarix Market (Million US$), 2010-2012Figure 5-1: Therapeutic Cancer Vaccines in Phase-3 Clinical Trials by Cancer Site (%)
List of Tables:
Table 3-1: Top 10 Cancer Incidences in Males (2012)Table 3-2: Top 10 Cancer Incidences in Females (2012)Table 4-1: Adverse Effects of GardasilTable 5-1: Cancers with High Linkage to Virus and BacteriaTable 5-2: Prophylactic Cancer Vaccines in Phase-4 Clinical TrialsTable 5-3: Prophylactic Cancer Vaccines in Phase-3 Clinical TrialsTable 5-4: Prophylactic Cancer Vaccines in Phase-2 Clinical TrialsTable 5-5: Prophylactic Cancer Vaccines in Phase-1 Clinical TrialsTable 5-6: Therapeutic Cancer Vaccines in Phase-3 Clinical TrialsTable 5-7: Prostate Cancer Therapeutic Vaccines in Phase-3 Clinical TrialsTable 5-8: Prostate Cancer Therapeutic Vaccines in Phase-2 Clinical TrialsTable 5-9: Prostate Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical TrialsTable 5-10: Breast Cancer Therapeutic Vaccines in Phase-3 Clinical TrialsTable 5-11: Breast Cancer Therapeutic Vaccines in Phase-2 Clinical TrialsTable 5-12: Breast Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical TrialsTable 5-13: Lung Cancer Therapeutic Vaccines in Phase-3 Clinical TrialsTable 5-14: Lung Cancer Therapeutic Vaccines in Phase-2 and 2/3 Clinical TrialsTable 5-15: Lung Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical TrialsTable 5-16: Colorectal Cancer Therapeutic Vaccines in Phase-2 Clinical TrialsTable 5-17: Colorectal Cancer Therapeutic Vaccines in Phase-1 and 1/2 Clinical TrialsTable 7-1: Merck - Cancer Vaccines in PipelineTable 7-2: GlaxoSmithKline - Cancer Vaccines in PipelineTable 7-3: Dendreon - Cancer Vaccines in PipelineTable 7-4: Bavarian Nordic - Cancer Vaccines in PipelineTable 7-5: Celldex Therapeutics - Cancer Vaccines in PipelineTable 7-6: KAEL-GemVax - Cancer Vaccines in PipelineTable 7-7: Oxford BioMedica - Cancer Vaccines in PipelineTable 7-8: Galena Biopharma - Cancer Vaccines in PipelineTo order this report:Drug_and_Medication Industry: US Cancer Vaccine Market Analysis
Intl: +1 805-652-2626
Copyright©2012 PR Newswire.
All rights reserved